$0.01
(0.83%)
Add to watchlist
Create an alert
Stocks and Shares ISARafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. The Company's segments include Healthcare, Infusion Technology and Real Estate. The Company’s lead candidate is Trappsol Cyclo, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder. The Healthcare segment comprises equity interests in LipoMedix Pharmaceuticals Ltd., Barer Institute Inc., Cornerstone Pharmaceuticals, Inc., Cyclo, and Rafael Medical Devices, LLC. The Real Estate segment consists of the Company’s real estate holdings, which comprise a portion of one commercial building in Israel. The Infusion Technology segment comprises equity interests in Day Three Labs, Inc. LipoMedix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company.
Company Information
About this company
Key people
Howard S. Jonas
Executive Chairman of the Board, President, Chief Executive Officer
David A. Polinsky
Chief Financial Officer
Joshua M. Fine
Chief Operating Officer
N. Scott Fine
Non-Executive Vice Chairman of the Board
Markus Walter Sieger
Lead Independent Director
Susan Bernstein
Director
Alan Grayson
Independent Director
Mark N. Stein
Independent Director
Click to see more
Key facts
- Shares in issue51.81m
- EPICRFL
- ISINUS75062E1064
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$62.12m
- Employees21
- ExchangeNew York Stock Exchange
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.